
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release